

## Freedom of Information Request: Our Reference CTMUHB\_257\_22

### You asked:

I have a freedom of information query regarding the use of Biologic medicines in Dermatology. Could you please tell me how many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

- Abatacept
- Adalimumab - Humira
- Adalimumab Biosimilar
- Apremilast
- Bimekizumab
- Brodalumab
- Certolizumab
- Dimethyl fumarate
- Etanercept - Enbrel
- Etanercept Biosimilar
- Golimumab
- Guselkumab
- Infliximab - Remicade
- Infliximab Biosimilar
- Ixekizumab
- Risankizumab
- Secukinumab
- Tildrakizumab
- Tofacitinib
- Ustekinumab
- Upadacitinib

### Our response:

Please find below a table populated with the data that Medicines Management are able to provide in relation to your request. The period relates to 1<sup>st</sup> June 2022 to 31<sup>st</sup> August 2022.

	Number of Patients
Abatacept	0
Adalimumab - Humira	**
Adalimumab Biosimilar	31
Apremilast	55
Bimekizumab	**
Brodalumab	0
Certolizumab	**
Dimethyl fumarate	**
Etanercept - Enbrel	0
Etanercept Biosimilar	**
Golimumab	0
Guselkumab	10

Infliximab - Remicade	0
Infliximab Biosimilar	7
Ixekizumab	10
Risankizumab	0
Secukinumab	0
Tildrakizumab	0
Tofacitinib	0
Ustekinumab	25
Upadacitinib	**

Where the figures are less than 5, this has been denoted by \*\*. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.